Amneal Pharmaceuticals, Inc. · NASDAQ:AMRX
Amneal Pharmaceuticals — Jefferies Healthcare Conference 2022
21 slides from Amneal Pharmaceuticals's conference presentation, Jun 8, 2022
Slide 1: Amneal Pharmaceuticals – Jefferies Healthcare Conference
Amneal Pharmaceuticals Jefferies Healthcare Conference June 8, 2022 g
Slide 2: Cautionary Statement on Forward Looking Statements
Cautionary Statement on Forward Looking Statements Certain statements contained in this presentation, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include
Slide 3: Amneal: We make healthy possible
Amneal: We make healthy possible® Amneal develops, manufactures, commercializes and distributes a growing and diverse portfolio of essential medicines, including complex generics, injectables, biosimilars and specialty branded pharmaceuticals. Through this diversified and innovative portfolio, we ar
Slide 4: Our strategy for growth as a global essential medicines company
Our strategy for growth as a global essential medicines company Business area Strategy for growth Growth projection(1) Grow our top 5 U.S. Generics portfolio of 225+ products with 20-30 new Retail Low-single digit growth product launches each year and increasingly focused on complex areas Expand por
Slide 5: Amneal’s commitment to innovation
Amneal’s commitment to innovation Reflects the timing of when a new product in each category was initially launched or is expected to launch by Amneal 2024-2025 2022 upcoming K-114 Biosimilars (Hypothyroidism, Illinois & Spain T4 sub-indication) Releuko® (filgrastim) Alymsys® 2024 2019 (bevacizumab)
Slide 6: Diversified portfolio with less concentration in oral solid Generics
GENERICS | SPECIALTY | AVKARE Diversified portfolio with less concentration in oral solid Generics Purposeful mix shift to more complex Generics portfolio Diversified and growing revenue base Generics net revenues mix ($’s) Pipeline mix Revenue contribution by business (# of products) 2021 revenues
Slide 7: Wheel of innovation expected to drive sustainable growth
GENERICS Wheel of innovation expected to drive sustainable growth Developing pipeline across increasingly complex dosage forms with 86% non-oral solids ~101 pipeline products with Oral Solids: 47 Injections: 28 Ophthal/Otic: 8 ~$38B TAM $17,887 $2,482 $2,612 $2,624 Pending $8,164 $952 ANDA’s $1,454
Slide 8: Scaling our injectables business to drive substantial growth
INJECTABLES Scaling our injectables business to drive substantial growth Expanding with new products and global capabilities will drive substantial Injectables revenue growth • Targeting 40+ launches through 2025 in a variety of complex $ millions areas, such as drug/device combinations, peptides, l
Slide 9: Entering U.S. biosimilar market with key oncology products
BIOSIMILARS Entering U.S. biosimilar market with key oncology products ~$4B TOTAL (1) Estimated U.S. market size for our first three U.S. approved ~$2B BIOSIMILARS oncology biosimilars Approved Our biosimilars strategy: Alymsys® Releuko® FylnetraTM biosimilars • Expanding portfolio through in-licens
Slide 10: Expanding branded portfolio expected to drive growth
SPECIALTY Expanding branded portfolio expected to drive growth Organic growth of existing products + New branded launches in the pipeline (1) + Business development 2022 2023 2024 2025 2026 $378M LYVISPAH® • Pursue strategic, accretive • Strong branded DHE transactions focused on Rytary Autoinjector
Slide 11: Branded pipeline expected to expand portfolio and create value
SPECIALTY Branded pipeline expected to expand portfolio and create value LYVISPAHTM DHE Autoinjector IPX-203 K-127 K-114 K-128 Product Baclofen oral granules Dihydroergotamine Carbidopa-levodopa Pyridostigmine QD, LT3 sustained release THP hydrochloride (FDA approved Nov. 2021) mesylate oral extende
Slide 12: Entering select international markets with impactful products
INTERNATIONAL Entering select international markets with impactful products (1) MARKET SIZE Expect to be commercial in $197B 2025 China late 2022 or early 2023 with 5 products filed and 10-15 planned for year-end, and more $168B over time with our partner Fosun TODAY Building a presence in India $36
Slide 13: Strong annual performance driven by innovation and execution
Strong annual performance driven by innovation and execution Net revenue growth Adjusted gross margin expansion Adjusted EBITDA growth $ millions % of net revenue $ millions 45.7% In-line ~$550 with $512 ~$2,200 2021 $2,094 $433 $1,993 41.6% (1) (1,2) 2020 Actual 2021 Actual 2022 Guidance 2020 Actua
Slide 14: Strengthening balance sheet and disciplined capital allocation
Strengthening balance sheet and disciplined capital allocation $ millions March 31, 2022 Capital allocation priorities are disciplined (1) and focused on long-term returns Current portion and long-term debt $2,703 (2) • Consistent investments in organic growth, specifically R&D, Cash and cash equiva
Slide 15: Amneal has a bolus of key catalysts over the next 18 months
Amneal has a bolus of key catalysts over the next 18 months Key upcoming catalysts • Every year: Expect 20-30 new product planned launches with focus on increasingly complex areas Retail • Select 2022/2023 planned launches include in Ophthalmics/Otics: gPred-Forte®, and gCiproDex®; in Inhalation/Nas
Slide 16: Focused on affordable, essential medicines for patients in need
Focused on affordable, essential medicines for patients in need Recently, first three U.S. biosimilars were approved with Releuko® (filgrastim-ayow), Alymsys® (bevacizumab-maly), and FyInetraTM Innovation (pegfilgrastim-pbbk) as we believe biosimilars are the next wave of U.S. affordable medicines A
Slide 17: Executing growth strategy and our outlook is bright
Executing growth strategy and our outlook is bright • On-track for 2022 growth commitments, which Executing well and continues the momentum from 2020 and 2021, and on-track for 2022 reflects diversity and durability of our growth profile • Entering the large and growing U.S. biosimilar Key new produ
Slide 18: Appendix: Non-GAAP Reconciliations
Appendix: Non-GAAP Reconciliations
Slide 19: Reconciliation of net (loss) income to EBITDA and adjusted results
Reconciliation of net (loss) income to EBITDA and adjusted results ($) in millions Three months ended Twelve Months Ended LTM March 31, 2022 March 31, 2021 December 31, 2021 December 31, 2020 March 31, 2022 Net (loss) income $ (6.5) $ 14.5 $ 20.1 $ 68.6 (0.9) Adjusted to add (deduct): - Interest exp
Slide 20: Reconciliation of cost of goods sold and gross profit to adjusted results
Reconciliation of cost of goods sold and gross profit to adjusted results ($) in millions Three months ended Twelve months ended March 31, 2022 March 31, 2021 December 31, 2021 December 31, 2020 Net Revenue $ 497.6 $ 493.1 $ 2,093.7 $ 1,992.5 Cost of goods sold 323.1 301.5 1,302.0 1,329.6 Cost of go
Slide 21: Reconciliation of cost of goods sold and gross profit to adjusted results
Reconciliation of cost of goods sold and gross profit to adjusted results Reconciliation of Generics Gross Profit to Adjusted Gross Profit ($) in millions Three Months Ended March 31, 2022 Three Months Ended March 31, 2021 Twelve Months Ended December 31, 2021 Twelve Months Ended December 31, 2020 A
Amneal Pharmaceuticals — Jefferies Healthcare Conference 2022 on 6ix